Abstract
The present work reports the effect of conjugation of the anticarcinogenic and antitumor soybean Bowman-Birk protease inhibitor (BBI) with amphiphilic block copolymer of ethylene oxide and propylene oxide (PEO-PPO) as well as with monoclonal antibody via clinical dextran (D) on tumor-targeted delivery of BBI.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / administration & dosage
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology*
-
Caco-2 Cells
-
Dextrans
-
Drug Carriers
-
Drug Delivery Systems
-
Epoxy Compounds
-
Ethylene Oxide
-
Fluorescent Antibody Technique
-
Humans
-
Immunoconjugates / administration & dosage*
-
Immunoconjugates / pharmacokinetics
-
Immunoconjugates / pharmacology*
-
Immunohistochemistry
-
Mice
-
Polymers
-
Tissue Distribution
-
Trypsin Inhibitor, Bowman-Birk Soybean / administration & dosage*
-
Trypsin Inhibitor, Bowman-Birk Soybean / pharmacokinetics
-
Trypsin Inhibitor, Bowman-Birk Soybean / pharmacology*
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Dextrans
-
Drug Carriers
-
Epoxy Compounds
-
Immunoconjugates
-
Polymers
-
Trypsin Inhibitor, Bowman-Birk Soybean
-
Ethylene Oxide
-
propylene oxide